Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data.

Author(s): Carreras E, Cahn JY, Puozzo C, Kroger N, Sanz G, Buzyn A, Bacigalupo A, Vernant JP

Affiliation(s): Institute of Hematology Oncology, 08036 Bacelona, Spain.

Publication date & source: 2010-07, Anticancer Res., 30(7):2977-84.

Publication type: Clinical Trial; Multicenter Study

This study investigated the effect of seizure prophylaxis on busulfan (Bu) plasma exposure. Twenty-four adult patients received an intravenous Bu-cyclophoshamide conditioning regimen prior to bone marrow transplantation. Busilvex (0.8 mg/kg) was administered every six hours during four consecutive days. Clonazepam (0.025 to 0.03 mg/kg/day as a continuous 12-h i.v. infusion) was administered at least 12 hours prior to i.v. Bu dosing and continued until 24 hours after the last dose. Pharmacokinetic (PK) data were compared with those previously collected in patients (n=127) treated with phenytoin for seizure prophylaxis. Through population PK analysis, a 10% average increase (coefficient of variation, RSE=5.35%) in total clearance of Bu was quantified when Bu was associated with clonazepam as compared to phenytoin, which was considered as not being clinically relevant. The suspected induction on Bu metabolism by phenytoin should have resulted in the opposite effect. The patient efficacy and safety profiles were comparable between the two cohorts.